SAT-112 CLINICAL TRIAL OF VENGLUSTAT, A GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITOR, IS SUPPORTED BY PRECLINICAL AND PHASE 1 STUDY DATA
Sign Up to like & getrecommendations! Published in 2019 at "Kidney International Reports"
DOI: 10.1016/j.ekir.2019.05.140
Abstract: results In three mouse models of PKD, treatment with a GCS inhibitor resulted in decreased kidney and plasma levels of glucosylceramide (GL-1) and reduced formation of kidney cysts compared with untreated controls. Analysis of kidney… read more here.
Keywords: gcs; venglustat; gcs inhibitor; kidney ... See more keywords